Subscribe
shutterstock_1819109333_mjgraphics-1
MJgraphics / Shutterstock.com
21 March 2023FeaturesBig PharmaSarah Speight

Humira: lessons from 20 years of patents, pricing and profits

Biotech multinational AbbVie has long reigned supreme in the biologics marketplace.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Abbvie seeks to block copycat of endometriosis drug
4 April 2023   Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.
Biotechnology
The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn
9 March 2023   The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process.
Generics
AbbVie and Alvotech settle all US Humira litigation
10 March 2022   AbbVie and Icelandic biosimilar company Alvotech have settled all US litigation over Alvotech’s proposed generic of AbbVie’s blockbuster arthritis treatment Humira (adalimumab).


Editor's picks

Squires: ‘Inherited patent backlog was an absolute dumpster fire’
Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025

Editor's picks

Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
23 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025
Americas
Top pharma, biotech, and medtech experts gather at LSPN Fall
21 October 2025
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025

More features

US generics company wins patent battle over Merck Serono’s blockbuster MS drug
Novartis counsel warns: ‘Don’t let AI develop without our input’
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
Delegates descend upon Washington, DC for AIPLA Annual Meeting
Novo Nordisk counters rival with $9bn bid for obesity drug developer
‘We're being attacked from all sides’: Thermo Fisher Scientific counsel
Edwards defends key heart valve product from infringement threat
The hidden code in life sciences deals